Surrogate Markers of Immune Function in Human Immunodeficiency Virus-Infected Patients: What Are They Surrogates For?

Journal of Infectious Diseases

Volumn 188, Issue 12, 2003, Pages 1791-1793

  Hengel, Richard L ^a,c   Kovacs, Joseph A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; RNA;

CELL PROLIFERATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE; MEMORY CELL; MOLECULAR RECOGNITION; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; RNA, VIRAL;

EID: 0347320478     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379901     Document Type: Editorial

References (11)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
2. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161-5.
3. + cell depletion. J Infect Dis 2003; 188:1794-803 (in this issue).
4. + cell count: a randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133: 493-503.
5. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
6. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:533-40.
7. Hengel RL, Jones BM, Kennedy MS, Hubbard MR, McDougal JS. Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. J Immunol 1999; 163:3539-48.
8. Pakker NG, Kroon ED, Roos MT, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999; 13:203-12.
9. + T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-61.
10. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 Team. AIDS Clinical Trials Group. AIDS 2000; 14:11-21.
11. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.